拉丁美洲多发性硬化和视神经脊髓炎谱系疾病的检测与治疗可及性数据集

数据集获取（Figshare）

• 源站标题：Multiple sclerosis and neuromyelitis optica spectrum disorder testing and treatment availability in Latin America
• DOI：10.6084/m9.figshare.14938231.v1
• 发布日期：2021-07-09
• 文件数：3 个
• 文件总体积：68.05 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Multiple_sclerosis_and_neuromyelitis_optica_spectrum_disorder_testing_and_treatment_availability_in_Latin_America/14938231

命令行下载

curl -L -o "yner_a_1949686_sm6816.docx" "https://ndownloader.figshare.com/files/28760491"
curl -L -o "yner_a_1949686_sm6814.docx" "https://ndownloader.figshare.com/files/28760494"
curl -L -o "yner_a_1949686_sm6812.docx" "https://ndownloader.figshare.com/files/28760497"

文件清单

• yner_a_1949686_sm6816.docx（28.96 KB）
• yner_a_1949686_sm6814.docx（18.31 KB）
• yner_a_1949686_sm6812.docx（20.77 KB）

文件总体积 68.05 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

The objective of our study was to describe the availability of diagnostic tests and treatment for MS and NMOSD in Latin America (LATAM).
A survey instrument was used in a sample of physicians from LATAM countries. The goal of the survey was to understand availability of: 1) imaging tests for diagnosing MS and NMOSD and its barriers; 2) diagnostic laboratory tests for diagnosing MS and NMOSD and its barriers; and 3) treatments for MS and NMOSD in the acute and chronic phases of the disease.
Responses were received from 80 physicians. AQP4-ab test was available in 54% of the countries and MOG-ab test in 42%. All of countries had available use of high doses of intravenous methylprednisolone, oral steroids, plasmapheresis, and intravenous immunoglobulins for relapses. For NMOSD, 93% of the countries were able to use azathioprine and mycophenolate mofetil, and 87% rituximab. In MS, 93% of countries had available to them IFN beta, 69% glatiramer acetate, 75% teriflunomide, 93% fingolimod, 69% dimethyl-fumarate, 75% cladribine, 69% natalizumab, 93% ocrelizumab and 81% alemtuzumab. The most common challenge and barrier identified was the cost of medications.
The present study allows an understanding of the delivery of care for MS and NMOSD in the region.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.14938231.v1（source: https://tandf.figshare.com/articles/dataset/Multiple_sclerosis_and_neuromyelitis_optica_spectrum_disorder_testing_and_treatment_availability_in_Latin_America/14938231）。